nor-Binaltorphimine (nor-BNI),kappa opioid receptor拮抗剂(ab120078)
Key features and details
- Potent and selective κ opioid receptor antagonist
- CAS Number: 113158-34-2
- Purity: > 98%
- Soluble in water to 50 mM
- Form / State: Solid
- Source: Synthetic
概述
-
产品名称
nor-Binaltorphimine (nor-BNI),kappa opioid receptor拮抗剂 -
描述
Potent and selective κ opioid receptor拮抗剂 -
别名
- nor-BNI
-
生物学描述
Potent and selective κ opioid receptor antagonist
-
纯度
> 98% -
CAS编号
113158-34-2 -
化学结构
性能
-
化学名称
17,17'-(Dicyclopropylmethyl)-6,6',7,7'-6,6'-imino-7,7'-binorphinan-3,4',14,14'-tetrol dihydrochloride -
分子量
734.72 -
分子式
C40H43N3O6.2HCl -
PubChem识别号
11957626 -
存放说明
Store at -20°C. Store under desiccating conditions. The product can be stored for up to 12 months. -
溶解度概述
Soluble in water to 50 mM -
处理
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
-
SMILES
C1CC1CN2CC[C@]34[C@@H]5C6=C(C[C@]3([C@H]2CC7=C4C(=C(C=C7)O)O5)O)C8=C(N6)[C@H]9[C@@]12CCN([C@@H]([C@@]1(C8)O)CC1=C2C(=C(C=C1)O)O9)CC1CC1.Cl.Cl -
来源
Synthetic
-
研究领域
图片
实验方案
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
文献 (9)
ab120078 被引用在 9 文献中.
- Makino Y et al. Comprehensive genomics in androgen receptor-dependent castration-resistant prostate cancer identifies an adaptation pathway mediated by opioid receptor kappa 1. Commun Biol 5:299 (2022). PubMed: 35365763
- Huang H et al. Antinociceptive Effects and Interaction Mechanisms of Intrathecal Pentazocine and Neostigmine in Two Different Pain Models in Rats. Pain Res Manag 2022:4819910 (2022). PubMed: 35646201
- Barbaro JM et al. Morphine disrupts macrophage functions even during HIV infection. J Leukoc Biol 112:1317-1328 (2022). PubMed: 36205434
- Wei YY et al. Novel selective κ agonists SLL-039 and SLL-1206 produce potent antinociception with fewer sedation and aversion. Acta Pharmacol Sin 43:1372-1382 (2022). PubMed: 34493813
- Zhai FJ et al. Involvement of Opioid Peptides in the Analgesic Effect of Spinal Cord Stimulation in a Rat Model of Neuropathic Pain. Neurosci Bull 38:403-416 (2022). PubMed: 35397112
- He Y et al. Transgenic increase in the ß-endorphin concentration in cerebrospinal fluid alleviates morphine-primed relapse behavior through the µ opioid receptor in rats. J Med Virol 91:1158-1167 (2019). PubMed: 30701563
- Sun J et al. Salvinorin A attenuates early brain injury through PI3K/Akt pathway after subarachnoid hemorrhage in rat. Brain Res 1719:64-70 (2019). PubMed: 31125530
- Azocar VH et al. The blocking of kappa-opioid receptor reverses the changes in dorsolateral striatum dopamine dynamics during the amphetamine sensitization. J Neurochem 148:348-358 (2019). PubMed: 30315655
- Li TF et al. Ester Hydrolysis Differentially Reduces Aconitine-Induced Anti-hypersensitivity and Acute Neurotoxicity: Involvement of Spinal Microglial Dynorphin Expression and Implications for Aconitum Processing. Front Pharmacol 7:367 (2016). PubMed: 27761113